A 4-week treatment with IMG-007 resulted in a mean reduction in eczema area and severity index (EASI) of 77% and…
Appointment adds business, market and partner development expertise to FYR board Addition highlights FYR’s evolution into partner of choice for…
Two additional TEASE-3 participants who recently completed 24 months of therapy showed no disease progression, consistent with prior results. A…
-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE…
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company…
The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health…
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment…
Presentation scheduled for Monday, January 13, 2025, at 4:30 PM PTNEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics,…
Revolutionary direct RNA-targeting technology opening a new frontier of prohibiting the production of proteins associated with diseaseDURHAM, N.C., Jan. 09,…
Azenosertib Fast Track Designation granted for Cyclin E1 positive patients by U.S. Food and Drug Administration (FDA) Manuscript focused on role…